Quick Answer
Corvus Pharmaceuticals, Inc. reported Net Income Loss of -$15.28 million for the year ending 2025.
- Corvus Pharmaceuticals, Inc. showed an increase of +75.5% in Net Income Loss from 2024 to 2025.
- This data is from Corvus Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: -$6.35 million | Q2 2016: -$8.65 million | Q3 2016: -$10.30 million | Q4 2016: -$11.09 million | Q1 2017: -$16.04 million | Q2 2017: -$14.98 million | Q3 2017: -$12.72 million | Q4 2017: -$11.93 million | Q1 2018: -$14.30 million | Q2 2018: -$11.63 million | Q3 2018: -$10.50 million | Q4 2018: -$10.51 million | Q1 2019: -$11.64 million | Q2 2019: -$12.98 million | Q3 2019: -$11.00 million | Q4 2019: -$11.05 million | Q1 2020: -$12.94 million | Q2 2020: -$10.61 million | Q3 2020: -$9.80 million | Q4 2020: $27.35 million | Q1 2021: -$11.58 million | Q2 2021: -$11.75 million | Q3 2021: -$10.67 million | Q1 2022: -$8.30 million | Q2 2022: -$8.36 million | Q3 2022: -$14.83 million | Q1 2023: -$7.87 million | Q2 2023: -$6.50 million | Q3 2023: -$6.00 million | Q1 2024: -$5.70 million | Q2 2024: -$4.26 million | Q3 2024: -$40.22 million | Q1 2025: $15.19 million | Q2 2025: -$8.00 million | Q3 2025: -$10.16 million.
- Over the full 12 years of available data (2014 to 2025), Corvus Pharmaceuticals, Inc.'s Net Income Loss has declined by 9,392.5%.
- Historical annual values: Fiscal year 2025: -$15.28 million | Fiscal year 2024: -$62.29 million | Fiscal year 2023: -$27.03 million | Fiscal year 2022: -$41.31 million | Fiscal year 2021: -$43.24 million | Fiscal year 2020: -$6.00 million | Fiscal year 2019: -$46.67 million | Fiscal year 2018: -$46.94 million | Fiscal year 2017: -$55.66 million | Fiscal year 2016: -$36.38 million | Fiscal year 2015: -$31.34 million | Fiscal year 2014: -$161.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: